Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
Level 5 - mechanism / opinion, no new human data
Narrative review of drug development, preclinical studies, and clinical data without systematic review methodology.
PubMed 23231438 · doi:10.1517/17460441.2013.741580
What was done
This narrative review summarizes the discovery, preclinical characterization, pharmacokinetics, toxicology, and clinical trial evidence for the GLP-1 receptor agonist exenatide (synthetic exendin-4, in immediate- and extended-release formulations) for treating type 2 diabetes mellitus.
What was found
The abstract reports no numerical data. Qualitatively, it reports that preclinical models demonstrated enhanced glucose-dependent insulin secretion, suppressed glucagon secretion, delayed gastric emptying, reduced weight, increased satiety, and preserved beta-cell function. In clinical trials, both formulations reduced hyperglycemia and promoted weight loss without increasing hypoglycemia risk compared to insulin therapy.
Why it matters
It chronicles the development of exenatide as the first-in-class GLP-1 receptor agonist, highlighting how peptide therapeutics can leverage incretin pathways to treat metabolic diseases.
Limits
The abstract provides no quantitative effect sizes, confidence intervals, or sample sizes. As a narrative review, it lacks a systematic search protocol and risk-of-bias assessment, presenting broad summary conclusions rather than original empirical data.
Cited by
- supports Exendin-4 was isolated and identified from the venom of the Gila monster.